Teleflex Reports Second Quarter Financial Results And Full Year Outlook

WAYNE, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 26, 2022.

Second quarter financial summary

  • Revenues of $704.5 million, down 1.3% year-over-year; up 2.3% on a constant currency basis
  • GAAP diluted EPS from continuing operations of $2.23, compared to $1.76 in the prior year period
  • Adjusted diluted EPS from continuing operations of $3.39, compared to $3.35 in the prior year period

2022 guidance summary

  • Reducing GAAP and constant currency revenue growth guidance to (0.45)% to 0.55% and 3.25% to 4.25%, respectively
  • Lowering GAAP EPS from continuing operations guidance to $8.04 to $8.44 from $8.85 to $9.45
  • Lowering adjusted diluted EPS from continuing operations guidance to $13.00 to $13.40 from $13.70 to $14.30

"Our second quarter results showed the resilience of our diverse portfolio of growth drivers and medically-necessary products," said Liam Kelly, Teleflex's Chairman, President and Chief Executive Officer. "Nonetheless, we did not see the expected operating environment recovery in our Interventional Urology business during the second quarter. Despite the near-term challenges, we remain committed to our multi-year strategy to drive growth in our high-growth portfolio and durable core, enhance margins, and advance our ESG initiatives."

NET REVENUE BY SEGMENT
The following table provides information regarding net revenues in each of the Company's reportable operating segments for the three and six months ended June 26, 2022 and June 27, 2021 on both a GAAP and constant currency basis.

 Three Months Ended % Increase / (Decrease)
 June 26, 2022 June 27, 2021 Reported
Revenue
Growth
 Currency
Impact
 Constant
Currency
Revenue Growth
Americas$412.7 $414.8 (0.5)% (0.2)% (0.3)%
EMEA 145.2  157.1 (7.6)% (11.0)% 3.4%
Asia 76.6  80.6 (5.0)% (6.8)% 1.8%
OEM 70.0  61.0 14.8% (2.8)% 17.6%
Total$704.5 $713.5 (1.3)% (3.6)% 2.3%


 Six Months Ended Six Months Ended
 June 26, 2022 June 27, 2021 Reported
Revenue
Growth
 Currency
Impact
 Constant
Currency
Revenue Growth
Americas$790.7 $790.3 0.1% (0.1)% 0.2%
EMEA 282.1  298.3 (5.5)% (8.9)% 3.4%
Asia 145.8  144.3 1.0% (5.6)% 6.6%
OEM 127.7  114.5 11.5% (2.2)% 13.7%
Total$1,346.3 $1,347.4 (0.1)% (2.8)% 2.7%

NET REVENUE BY GLOBAL PRODUCT CATEGORY
The following table provides information regarding net revenues in each of the Company's global product categories for the three and six months ended June 26, 2022 and June 27, 2021 on both a GAAP and constant currency basis.

 Three Months Ended % Increase / (Decrease)
 June 26, 2022 June 27, 2021 Reported
Revenue
Growth
 Currency
Impact
 Constant
Currency
Revenue Growth
Vascular Access$163.9 $167.7 (2.3)% (3.3)% 1.0%
Interventional 114.4  112.1 2.0% (3.3)% 5.3%
Anesthesia 104.7  95.4 9.7% (4.7)% 14.4%
Surgical 99.6  98.2 1.5% (4.4)% 5.9%
Interventional Urology 79.8  92.2 (13.5)% (0.3)% (13.2)%
OEM 70.0  61.0 14.8% (2.8)% 17.6%
Other 72.1  86.9 (16.9)% (6.0)% (10.9)%
Total$704.5 $713.5 (1.3)% (3.6)% 2.3%

        

 Six Months Ended Six Months Ended
 June 26, 2022 June 27, 2021 Reported
Revenue
Growth
 Currency
Impact
 Constant
Currency
Revenue Growth
Vascular Access$330.1 $331.7 (0.5)% (2.6)% 2.1%
Interventional 211.3  208.3 1.4% (2.5)% 3.9%
Anesthesia 191.6  180.3 6.3% (3.6)% 9.9%
Surgical 189.3  178.6 6.0% (3.8)% 9.8%
Interventional Urology 154.7  165.6 (6.6)% (0.2)% (6.4)%
OEM 127.7  114.5 11.5% (2.2)% 13.7%
Other 141.6  168.5 (15.9)% (4.6)% (11.3)%
Total$1,346.3 $1,347.4 (0.1)% (2.8)% 2.7%

OTHER FINANCIAL HIGHLIGHTS

  • Depreciation expense, amortization of intangible assets and deferred financing charges for the six months ended June 26, 2022 totaled $116.7 million compared to $122.2 million for the prior year period.
  • Cash and cash equivalents at June 26, 2022 were $308.1 million compared to $445.1 million at December 31, 2021.
  • Net accounts receivable at June 26, 2022 were $415.3 million compared to $383.6 million at December 31, 2021.
  • Inventories at June 26, 2022 were $510.5 million compared to $477.6 million at December 31, 2021.

2022 OUTLOOK
On a GAAP basis, full year 2022 revenue growth outlook is now expected to be (0.45)% to 0.55%, reflecting our estimate of an approximately 3.70% negative impact of foreign exchange rate fluctuations. On a constant currency basis, the Company revised its full year 2022 revenue growth guidance to 3.25% to 4.25% from 4.0% to 5.5%, inclusive of a year-over-year headwind from the initial phase of the respiratory divestiture completed on June 28, 2021, which is now expected to be approximately 1.10%.

The Company revised its full year 2022 GAAP diluted earnings per share from continuing operations outlook to $8.04 to $8.44 from $8.90 to $9.50. The Company lowered its 2022 adjusted diluted earnings per share from continuing operations guidance to $13.00 to $13.40 from $13.70 to $14.30, which includes a headwind from the respiratory divestiture now expected to be $0.16, representing a 2.5% decline to a 0.5% increase on a year-over-year basis.

Forecasted 2022 Constant Currency Revenue Growth Reconciliation

 Low High
Forecasted 2022 GAAP revenue growth(0.45)% 0.55%
Estimated impact of foreign currency exchange rate fluctuations(3.70)% (3.70)%
Forecasted 2022 constant currency revenue growth3.25% 4.25%

Forecasted 2022 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation

 Low High
Forecasted GAAP diluted earnings per share from continuing operations$8.04 $8.44
Restructuring, restructuring related and impairment items, net of tax$0.84 $0.84
Acquisition, integration and divestiture related items, net of tax$0.04 $0.04
Other-$0.02 -$0.02
MDR$0.79 $0.79
Intangible amortization expense, net of tax$3.31 $3.31
Forecasted adjusted diluted earnings per share from continuing operations$13.00 $13.40

CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION
A webcast of Teleflex's second quarter 2022 investor conference call can be accessed live from a link on the Company's website at teleflex.com. The call will begin at 8:00 am ET on July 28, 2022.

An audio replay of the investor call will be available beginning at 11:00 am ET on July 28, 2022, either on the Teleflex website or by telephone. The call can be accessed by dialing (866) 813-9403 (U.S.), 1 226 828 7578 (Canada), 0204 525 0658 (UK), 44 204 525 0658 (all other locations).

The confirmation code is 245144.

ADDITIONAL NOTES
References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.

In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.
Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations.

NOTES ON NON-GAAP FINANCIAL MEASURES
We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP.” In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: constant currency revenue growth and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

Tables reconciling changes in historical constant currency net revenues to historical GAAP net revenues are set forth above under “Net Revenue by Segment" and "Net Revenue by Global Product Category". Tables reconciling historical adjusted diluted earnings per share from continuing operations to historical GAAP diluted earnings per share from continuing operations are set forth below.

Constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.

Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Restructuring, restructuring related and impairment items - Restructuring programs involve discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies and integrate acquired businesses. Depending on the specific restructuring program involved, our restructuring charges may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement and other exit costs associated with the restructuring program.  Restructuring related charges are directly related to our restructuring programs and consist of facility consolidation costs, including accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of the restructuring program. Impairment charges occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.

Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions.  These charges may include, among other things, professional, consulting and other fees; systems integration costs; legal entity restructuring expense; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; and bridge loan facility and backstop financing fees in connection with loan facilities that ultimately were not utilized. Divestiture related activities involve specific business or asset sales.  Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.

European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance.  The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until May 2024, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices.  As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).

Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.

Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.

Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

Three Months Ended June 26, 2022
 Gross
margin
Selling,
general and
administrative
expenses
(1)
Research and
development
expenses
(1)
Operating
margin
(2)
Income before
income taxes
Income tax
expense
Effective
income tax
rate
Diluted
earnings per
share from
continuing
operations
GAAP Basis55.2% 30.8% 5.2% 19.2% $124.0$18.414.9% $2.23 
Adjustments        
Restructuring, restructuring related and impairment items (A)1.3   1.3  9.0 0.8  0.17 
Acquisition, integration and divestiture related items (B) (0.1)  0.1  0.5 0.1  0.01 
Other items        0.00 
MDR  (1.2) 1.2  8.5   0.18 
Intangible amortization expense3.1 (2.6)  5.7  40.5 1.5  0.82 
Tax adjustments      1.1  (0.02) 
Adjustments total4.4 (2.7) (1.2) 8.3  58.5 3.5  1.16 
Adjusted basis59.6% 28.1% 4.0% 27.5% $182.5$21.912.0% $3.39 

Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues.
(2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues.
Totals may not sum due to rounding.

Three Months Ended June 27, 2021
 Gross
margin
Selling,
general and
administrative
expenses
(1)
Research and
development
expenses
(1)
Operating
margin
(2)
Income before
income taxes
Income tax
expense
Effective
income tax
rate
Diluted
earnings per
share from
continuing
operations
GAAP Basis55.7% 31.4% 4.7% 18.0% $99.7$16.4 16.5% $1.76
Adjustments        
Restructuring, restructuring related and impairment items (A)1.0 (0.1)  2.7  19.5 1.4   0.38
Acquisition, integration and divestiture related items (B) (0.9)  0.9  6.1 0.3   0.12
Other items (C)   0.1  13.0 3.0   0.21
MDR  (0.8) 0.7  5.2    0.11
Intangible amortization expense3.1 (2.7)  5.9  41.9 7.0   0.74
Tax adjustments      (1.4)   0.03
Adjustments total4.1 (3.7) (0.8) 10.3  85.8 10.2   1.59
Adjusted basis59.9% 27.7% 3.9% 28.2% $185.5$26.5 14.4% $3.35

Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues.
(2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues.
Totals may not sum due to rounding.

Six Months Ended June 26, 2022
 Gross
margin
Selling,
general and
administrative
expenses
(1)
Research and
development
expenses
(1)
Operating
margin
(2)
Income before
income taxes
Income tax
expense
Effective
income tax
rate
Diluted
earnings per
share from
continuing
operations
GAAP Basis54.6% 31.3% 5.4% 17.7% $217.3$34.415.8% $3.86 
Adjustments        
Restructuring, restructuring related and impairment items (A)1.1   1.3  17.8 1.9  0.34 
Acquisition, integration and divestiture related items (B)     0.6   0.01 
Other items        0.00 
MDR  (1.5) 1.6  20.6   0.43 
Intangible amortization expense3.3 (2.9)  6.1  81.2 3.0  1.65 
Tax adjustments      1.1  (0.02) 
Adjustments total4.4 (2.9) (1.5) 9.0  120.2 6.0  2.41 
Adjusted basis59.0% 28.4% 3.9% 26.7% $337.5$40.412.0% $6.27 
         

Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues.
(2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues.
Totals may not sum due to rounding.

Six Months Ended June 27, 2021
 Gross
margin
Selling,
general and
administrative
expenses
(1)
Research and
development
expenses
(1)
Operating
margin
(2)
Income before
income taxes
Income tax
expense
Effective
income tax
rate
Diluted
earnings per
share from
continuing
operations
GAAP Basis55.1% 31.7% 4.7% 17.2% $187.0$28.8 15.4% $3.34
Adjustments        
Restructuring, restructuring related and impairment items (A)1.0   2.5  34.1 3.5   0.64
Acquisition, integration and divestiture related items (B)0.2 (1.0)  1.2  16.3 1.4   0.31
Other items (C)     13.0 3.0   0.21
MDR  (0.7) 0.7  9.4    0.20
Intangible amortization expense3.3 (2.9)  6.2  83.9 14.0   1.47
Tax adjustments      (2.0)   0.04
Adjustments total4.6 (3.9) (0.7) 10.7  156.7 19.9   2.88
Adjusted basis59.7% 27.8% 4.0% 27.9% $343.6$48.8 14.2% $6.23

Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues.
(2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues.
Totals may not sum due to rounding.

Tickmarks to Reconciliation Tables

(A)   Restructuring, restructuring related and impairment items – For the three months ended June 26, 2022, pre-tax restructuring charges were $(0.1) million and restructuring related charges were $9.1 million. For the three months ended June 27, 2021, pre-tax restructuring charges were $4.8 million; pre-tax restructuring related charges were $8.0 million; and pre-tax impairment charges were $6.7 million. For the six months ended June 26, 2022, pre-tax restructuring charges were $0.8 million, restructuring related charges were $15.5 million, and impairment charges were $1.5 million. For the six months ended June 27, 2021, pre-tax restructuring charges were $12.8 million; pre-tax restructuring related charges were $14.6 million; and pre-tax impairment charges were $6.7 million.

(B)   Acquisition, integration and divestiture related items – For the three months ended June 26, 2022, these charges related to the divestiture of respiratory assets. For the three months ended June 27, 2021, these charges primarily related to contingent consideration liabilities, charges primarily related to our divestiture of certain respiratory assets, and a reversal of previously recognized income related to a distributor conversion in Japan. For the six months ended June 26, 2022, these charges related to the divestiture of respiratory assets. For the six months ended June 27, 2021, these charges primarily related to contingent consideration liabilities, inventory step up for the Z-Medica LLC acquisition, and charges primarily related to our divestiture of certain respiratory assets.

(C) Other – For the three and six months ended June 27, 2021 other costs were associated with debt extinguishment.

ABOUT TELEFLEX INCORPORATED

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation - a relentless pursuit of identifying unmet clinical needs - to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®, QuikClot®, Rusch®, UroLift®, and Weck® - trusted brands united
by a common sense of purpose.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION
This press release contains forward-looking statements, including, but not limited to, statements regarding forecasted 2022 GAAP and constant currency revenue growth and GAAP and adjusted diluted earnings per share; our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2022 financial results; and our estimates with regard to the projected impacts of the divestiture of a significant portion of our respiratory business on our financial results.   Actual results could differ materially from those in the forward-looking statements due to, among other things, the adverse economic conditions associated with the COVID-19 global health pandemic and the associated financial crisis, stay-at-home and other orders, which may significantly reduce customer spending and which may have a negative impact on the Company’s business, changes in business relationships with and purchases by or from major customers or suppliers; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; the inability of acquired businesses to generate revenues in accordance with our expectations; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, sovereign debt issues and international conflicts and hostilities, such as the ongoing geopolitical conflicts between Russia and Ukraine; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

TELEFLEX INCORPORATED
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

 Three Months Ended Six Months Ended
 June 26, 2022 June 27, 2021 June 26, 2022 June 27, 2021
  
 (Dollars and shares in thousands, except per share)
Net revenues$704,542  $713,473  $1,346,257  $1,347,398 
Cost of goods sold 315,709   315,917   611,191   605,315 
Gross profit 388,833   397,556   735,066   742,083 
Selling, general and administrative expenses 216,825   224,159   420,757   427,307 
Research and development expenses 36,934   33,283   73,294   63,230 
Restructuring and impairment (credits) charges (83)  11,494   2,322   19,492 
Income from continuing operations before interest and taxes 135,157   128,620   238,693   232,054 
Interest expense 11,419   16,171   21,837   32,969 
Interest income (229)  (232)  (451)  (891)
Loss on extinguishment of debt    12,986      12,986 
Income from continuing operations before taxes 123,967   99,695   217,307   186,990 
Taxes on income from continuing operations 18,412   16,412   34,385   28,840 
Income from continuing operations 105,555   83,283   182,922   158,150 
Operating loss from discontinued operations (54)  (46)  (348)  (47)
Tax benefit on operating loss from discontinued operations (13)  (11)  (81)  (11)
Loss from discontinued operations (41)  (35)  (267)  (36)
Net income$105,514  $83,248  $182,655  $158,114 
Earnings per share:       
Basic:       
Income from continuing operations$2.25  $1.78  $3.90  $3.39 
Loss from discontinued operations          (0.01)
Net income$2.25  $1.78  $3.90  $3.38 
Diluted:       
Income from continuing operations$2.23  $1.76  $3.86  $3.34 
Loss from discontinued operations          (0.01)
Net income$2.23  $1.76  $3.86  $3.33 
Weighted average common shares outstanding       
Basic 46,901   46,741   46,889   46,719 
Diluted 47,347   47,433   47,374   47,420 

TELEFLEX INCORPORATED
CONSOLIDATED BALANCE SHEETS
(Unaudited)

 June 26, 2022 December 31, 2021
  
 (Dollars in thousands)
ASSETS   
Current assets   
Cash and cash equivalents$308,121 $445,084
Accounts receivable, net 415,297  383,569
Inventories 510,531  477,643
Prepaid expenses and other current assets 112,595  117,277
Prepaid taxes 38,801  5,545
Total current assets 1,385,345  1,429,118
Property, plant and equipment, net 429,372  443,758
Operating lease assets 118,620  129,653
Goodwill 2,461,083  2,504,202
Intangible assets, net 2,226,875  2,289,067
Deferred tax assets 6,243  6,820
Other assets 104,308  69,104
Total assets$6,731,846 $6,871,722
LIABILITIES AND EQUITY   
Current liabilities   
Current borrowings$110,000 $110,000
Accounts payable 121,418  118,236
Accrued expenses 151,715  163,441
Payroll and benefit-related liabilities 114,384  143,657
Accrued interest 4,751  5,209
Income taxes payable 52,174  83,943
Other current liabilities 56,004  55,633
Total current liabilities 610,446  680,119
Long-term borrowings 1,605,954  1,740,102
Deferred tax liabilities 379,931  370,124
Pension and postretirement benefit liabilities 42,097  45,185
Noncurrent liability for uncertain tax positions 8,543  8,646
Noncurrent operating lease liabilities 104,702  116,033
Other liabilities 127,443  156,765
Total liabilities 2,879,116  3,116,974
Commitments and contingencies   
Total shareholders' equity 3,852,730  3,754,748
Total liabilities and shareholders' equity$6,731,846 $6,871,722
      

TELEFLEX INCORPORATED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

 Six Months Ended
 June 26, 2022 June 27, 2021
  
 (Dollars in thousands)
Cash flows from operating activities of continuing operations:   
Net income$182,655  $158,114 
Adjustments to reconcile net income to net cash provided by operating activities:   
Loss from discontinued operations 267   36 
Depreciation expense 33,499   35,982 
Intangible asset amortization expense 81,137   83,867 
Deferred financing costs and debt discount amortization expense 2,103   2,388 
Loss on extinguishment of debt    12,986 
Fair value step up of acquired inventory sold    3,993 
Changes in contingent consideration 145   11,428 
Asset impairment charges 1,497   6,739 
Stock-based compensation 12,801   11,693 
Deferred income taxes, net 937   1,050 
Payments for contingent consideration (2,722)   
Interest benefit on swaps designated as net investment hedges (10,145)  (9,126)
Other (1,779)  (16,679)
Changes in assets and liabilities, net of effects of acquisitions and disposals:   
Accounts receivable (43,939)  (23,159)
Inventories (48,682)  (13,648)
Prepaid expenses and other assets 15,464   (16,551)
Accounts payable, accrued expenses and other liabilities (38,722)  32,625 
Income taxes receivable and payable, net (82,657)  (16,663)
     Net cash provided by operating activities from continuing operations 101,859   265,075 
Cash flows from investing activities of continuing operations:   
Expenditures for property, plant and equipment (32,445)  (36,659)
Proceeds from sale of business and assets 530   404 
Payments for businesses and intangibles acquired, net of cash acquired (22,971)  (3,539)
Deposits    (1,250)
Net interest proceeds on swaps designated as net investment hedges 10,314   9,288 
Net cash used in investing activities from continuing operations (44,572)  (31,756)
Cash flows from financing activities of continuing operations:   
Proceeds from new borrowings    400,000 
Reduction in borrowings (135,500)  (575,000)
Debt extinguishment, issuance and amendment fees    (9,774)
Net (payments) proceeds from share based compensation plans and related tax impacts (4,366)  6,339 
Payments for contingent consideration (3,012)  (30,489)
Dividends paid (31,892)  (31,793)
Net cash used in financing activities from continuing operations (174,770)  (240,717)
Cash flows from discontinued operations:   
Net cash used in operating activities (280)  (371)
Net cash used in discontinued operations (280)  (371)
Effect of exchange rate changes on cash and cash equivalents (19,200)  (6,330)
Net decrease in cash and cash equivalents (136,963)  (14,099)
Cash and cash equivalents at the beginning of the period 445,084   375,880 
Cash and cash equivalents at the end of the period$308,121  $361,781 

Contacts:
Teleflex Incorporated:
Lawrence Keusch
Vice President, Investor Relations and Strategy Development

John Hsu, CFA
Vice President, Investor Relations

investors.teleflex.com
610-948-2836


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.